Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

VREX vs LGL.WS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VREX Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 10–0 Matrix Metrics)

VREX Overall Winner 6-Pillar Tally: VREX 5 – 0 LGL.WS (1 Tie) Matrix Metrics: VREX 10 – 0 LGL.WS

As of Nov 20, 2026, Varex Imaging Corporation (VREX) is the stronger overall head-to-head candidate over LGL Group Inc (The) Warrants to purchase (LGL.WS) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VREX carries a Unified Composite Score of 54.8/100 (HOLD) at $18.10 (16.9x Forward P/E, 8.3% operating margin), whereas LGL.WS carries 49.1/100 (HOLD) at $0.17 (N/M Forward P/E, N/A operating margin).

  • Technical & Structure Timing Caution: VREX is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 28.4); meanwhile LGL.WS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VREX vs LGL.WS
VREX NASDAQ Head-to-Head Winner
Varex Imaging Corporation Common Stock
Electronic Components, Nec
$18.10
-0.22% 1D
Market Cap $770.3M
TTM Revenue $865M
Forward P/E 16.9x
Beta / 30D Vol 0.65β · 5% Vol
Unified Composite Score
54.8 / 100 HOLD
Tech 46.0 Fund 45.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -0.3%) with fading momentum, RSI 28
RSI-14: 28.4 · SMA20: $18.34 · SMA50: $18.41
LGL.WS NYSE American
LGL Group Inc (The) Warrants to purchase Common Stock (expiring November 16, 2025)
Electronic Components, Nec
$0.17
-4.51% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol N/A
Unified Composite Score
49.1 / 100 HOLD
Tech 60.0 Fund 54.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A

6-Pillar Scorecard Institutional Category Breakdown (VREX 5 – 0 LGL.WS)

Columns: Metric · VREX · LGL.WS
1. Valuation Multiples VREX
Forward P/E 16.9x N/M
Trailing P/E 34.2x N/M
PEG Ratio 6.30x N/M
EV / Revenue 0.9x N/M
2. Growth & Scale VREX
Revenue Growth (YoY) +3.7% N/A
Earnings Growth (YoY) +453.4% N/A
TTM Revenue (USD) $865M N/A
Market Cap $770.3M N/A
3. Profitability & Quality VREX
Gross Margin 34.3% N/A
Operating Margin 8.3% N/A
Net Profit Margin 2.6% N/A
Return on Equity (ROE) 4.6% N/A
4. Balance Sheet & Cash Flow VREX
Cash Generation (TTM) $100M EBITDA N/A
Cash Flow Margin 11.5% EBITDA Mgn N/A
Net Cash / Leverage $11.78 Book/Sh · 4.6% ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 112.0% (18th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Distribution NEUTRAL · Neutral
6. R&D & Supply-Chain Moat VREX
OpEx & R&D Intensity 26.0% of Rev ($225M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Electronic Components, Nec Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VREX (10) vs LGL.WS (0)
Institutional Metric VREX LGL.WS Criterion Row Edge
Market Capitalization
Scale
$770.3M N/A Larger Scale VREX
Trailing P/E Ratio
Valuation
34.2x N/M Lower Multiple VREX
Forward P/E Ratio
Valuation
16.9x N/M Lower Multiple VREX
Revenue Growth (YoY)
Growth
+3.7% N/A Higher Growth VREX
Operating Margin (TTM)
Profitability
8.3% N/A Higher Margin VREX
Net Profit Margin
Profitability
2.6% N/A Higher Margin VREX
Return on Equity (ROE)
Capital Efficiency
4.6% N/A Higher ROE VREX
52-Week Range Position
Momentum
94% ($9–$19) 0% ($0–$0) Stronger Trend VREX
Beta / 30D Volatility
Risk Regime
0.65β · 5% Vol N/A Lower Realized Risk VREX
Unified Institutional Score
Composite Signal
54.8 / 100 (HOLD) 49.1 / 100 (HOLD) Higher Composite VREX
Trailing 12M Revenue (USD)
Operating Scale
$865M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
34.3% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
6.30x PEG · 0.9x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$100M EBITDA ($11.78 Book/Sh · 4.6% ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VREX +47.86 pp
VREX: +11.34% · LGL.WS: -36.52%
3M Horizon VREX +47.86 pp
VREX: +11.34% · LGL.WS: -36.52%
6M Horizon VREX +47.86 pp
VREX: +11.34% · LGL.WS: -36.52%
1Y Horizon VREX +47.86 pp
VREX: +11.34% · LGL.WS: -36.52%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VREX vs LGL.WS. Trailing 12-month operating profitability (VREX 8.3% vs LGL.WS N/A) and valuation multiples (VREX 16.9x vs LGL.WS N/M Forward P/E) are benchmarked directly in Pillar 4 below.

VREX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$865M
Gross Margin34.3%
Op. Margin8.3%
ROE / Fwd P/E4.6% · 16.9x
LGL.WS ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VREX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 112.0%
IV Percentile 18th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VREX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LGL.WS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact LGL.WS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VREX Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $770.3M market capitalization and 8.3% operating margin.
OpEx & R&D Reinvestment 26.0% of Rev ($225M)
90D Engineering Disclosures 0 Published
LGL.WS Moat Profile Cyclical / Execution-Driven Positioning
Electronic Components, Nec Operator
Competes within the Electronic Components, Nec value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VREX vs LGL.WS Key Questions & Quantitative Answers

As of Nov 20, 2026, Varex Imaging Corporation (VREX) is the stronger overall head-to-head candidate over LGL Group Inc (The) Warrants to purchase (LGL.WS) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VREX carries a Unified Composite Score of 54.8/100 (HOLD) at $18.10 (16.9x Forward P/E, 8.3% operating margin), whereas LGL.WS carries 49.1/100 (HOLD) at $0.17 (N/M Forward P/E, N/A operating margin). Technical & Structure Timing Caution: VREX is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 28.4); meanwhile LGL.WS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VREX leads the Growth & Scale pillar: VREX posts +3.7% YoY revenue growth and +453.4% YoY earnings growth on $865M TTM revenue (34.3% gross margin, 8.3% operating margin), compared with LGL.WS at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, VREX generates $865M in USD-normalized revenue versus N/A for LGL.WS. In operating R&D and SG&A reinvestment, VREX deploys 26.0% of Rev ($225M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LGL.WS.

VREX screens cheaper on headline valuation multiples. VREX trades at 16.9x Forward P/E, 34.2x Trailing P/E, 6.30x PEG, and 0.9x EV/Revenue (11.5% EBITDA margin), whereas LGL.WS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VREX (4.6% ROE) versus LGL.WS (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, VREX carries 112.0% implied volatility (18th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.65β · 5% Vol realized risk). By comparison, LGL.WS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (N/A realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.